SCHEMBL5859863

SCHEMBL5859863

O=C(O)C=Cc1ccc2c(c1Br)OCO2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
AR P10275 1/20 0.45
CYP1A2 P05177 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
EIF2AK2 P19525 1/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
MAOB P27338 4/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
NFKB1 P19838 1/20 0.40
CA4 P22748 1/20 0.40
AOC3 Q16853 1/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
CNKSR1 Q969H4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5859861 1.00 KDM4E (0.50) KDM4EARCYP1A2HSD17B10KMT2A
SCHEMBL6851140 0.80 KDM4E (0.57) KDM4EARCYP1A2HSD17B10MAOB
SCHEMBL8726252 0.80 KDM4E (0.57) KDM4EARCYP1A2HSD17B10MAOB
SCHEMBL162075 0.80 KDM4E (0.77) KDM4EARCYP1A2HSD17B10MAOB
SCHEMBL162076 0.80 KDM4E (0.77) KDM4EARCYP1A2HSD17B10MAOB
SCHEMBL30330011 0.79 TDP1 (0.44) HSD17B10KMT2AATMAOC3MAPT
SCHEMBL10620285 0.79 TDP1 (0.44) HSD17B10KMT2AATMAOC3MAPT
SCHEMBL7822146 0.78 KDM4E (0.47) KDM4EARCYP1A2HSD17B10MAOB
SCHEMBL9786077 0.78 KDM4E (0.47) KDM4EARCYP1A2HSD17B10MAOB
SCHEMBL9786078 0.78 KDM4E (0.47) KDM4EARCYP1A2HSD17B10MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989384-B2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis AGOURON PHARMACEUTICALS, INC. (US) 2006-01-24 US disclosed
US-20050080121-A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis AGOURON PHARMACEUTICALS, INC. 2005-04-14 US disclosed
EP-1355878-A2 ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS AGOURON PHARMACEUTICALS, INC. (US) 2003-10-29 EP disclosed
US-6632825-B2 Picornaviral 3C protease enzyme inhibitors; amide ester or amide acid derivatives AGOURON PHARMACEUTICALS, INC. 2003-10-14 US disclosed
US-20020061916-A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis AGOURON PHARMACEUTICALS, INC. 2002-05-23 US disclosed
WO-2001096297-A2 ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS AGOURON PHARMACEUTICALS, INC. (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080121-A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis PRCP, RNPEP, SARNP KDM4E 3080/4885AR 4197/4885CYP1A2 2607/4885
US-20020061916-A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis PRCP, RNASEL, RNASEH1 KDM4E 3119/4885AR 4106/4885CYP1A2 2545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.